TP-271

fully synthetic fluorocycline with activity against Francisella tularensis

Also Known As:

(2S)-N-((5aR,6aS,7S,10aR)-9-carbamoyl-7-(dimethylamino)-4-fluoro-1,10,10a,12-tetrahydroxy-8,11-dioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl)-1-methylpyrrolidine-2-carboxamide

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthacenes
        Tetracyclines: 1162
        TP-271: 3
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthacenes
    - Tetracyclines: 1162
      - TP-271: 3

Experts

1.	Grossman, Trudy H: 3 articles (10/2017 - 01/2017)
2.	Sutcliffe, Joyce A: 3 articles (10/2017 - 01/2017)
3.	Anderson, Michael S: 2 articles (10/2017 - 01/2017)
4.	Gooldy, Melanie: 2 articles (10/2017 - 01/2017)
5.	Heine, Henry S: 2 articles (10/2017 - 01/2017)
6.	Henning, Lisa N: 2 articles (10/2017 - 01/2017)
7.	Lin, Winston: 2 articles (10/2017 - 01/2017)
8.	Radcliff, Anne K: 2 articles (10/2017 - 01/2017)
9.	Siefkas-Patterson, Kaylyn: 2 articles (10/2017 - 01/2017)
10.	Drabek, Lindsay: 1 article (10/2017)

Related Diseases

1.	Bacterial Pneumonia 01/01/2017 - "Fluorocycline TP-271 Is Potent against Complicated Community-Acquired Bacterial Pneumonia Pathogens." 01/01/2017 - "TP-271 was potent against key community-acquired bacterial pneumonia (CABP) pathogens and was minimally affected, or unaffected, by tetracycline-specific resistance mechanisms and fluoroquinolone or macrolide drug resistance phenotypes. "
2.	Body Weight (Weight, Body) 10/01/2017 - "When 21 days of once-daily dosing was initiated at 24 h postchallenge (the postexposure prophylaxis [PEP] study), the rates of survival for the groups treated with TP-271 at 3, 6, 12, and 18 mg/kg of body weight were 90%, 95%, 95%, and 84%, respectively. " 01/01/2017 - "Following 21 days of once-daily intraperitoneal dosing with TP-271 at 3, 6, 12, and 18 mg/kg of body weight/day, initiating at 24 h postchallenge, survival was 80%, 100%, 100%, and 100%, respectively. "
3.	Respiratory Tract Infections (Respiratory Tract Infection) 01/01/2017 - "TP-271 is a novel, fully synthetic fluorocycline in development for complicated bacterial respiratory infections. " 01/01/2017 - "TP-271 is a novel, fully synthetic fluorocycline antibiotic in clinical development for the treatment of respiratory infections caused by susceptible and multidrug-resistant pathogens. "
4.	Infections 01/01/2017 - "The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Francisella tularensis SCHU S4 Infection in BALB/c Mice and Cynomolgus Macaques." 01/01/2017 - "TP-271 was efficacious in neutropenic and immunocompetent animal pneumonia models, generally showing, compared to the burden at the start of dosing, ~2 to 5 log10 CFU reductions against MRSA, S. pneumoniae, and H. influenzae infections when given intravenously (i.v.) and ~1 to 4 log10 CFU reductions when given orally (p.o.). "
5.	Pneumonia (Pneumonitis) 01/01/2017 - "TP-271 was efficacious in neutropenic and immunocompetent animal pneumonia models, generally showing, compared to the burden at the start of dosing, ~2 to 5 log10 CFU reductions against MRSA, S. pneumoniae, and H. influenzae infections when given intravenously (i.v.) and ~1 to 4 log10 CFU reductions when given orally (p.o.). "

Related Drugs and Biologics

1.	Fluoroquinolones
2.	Macrolides
3.	Tetracycline (Achromycin)
4.	Anti-Bacterial Agents (Antibiotics)

Related Therapies and Procedures

1.	Intravenous Infusions